References
- Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817–1826.
- Karube K, Campo E. MYC alterations in Diffuse Large B-cell Lymphomas. Semin Hematol 2015;52:97–106.
- Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009;114:2273–2279.
- Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/CCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype diffuse large B-cell lymphoma and demonstrates high-risk gene expression. Blood 2013;121:4021–4031.
- Zhou K, Xu D, Cao Y, et al. c-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies. PLoS One 2014;9:e95020.
- Caponetti GC, Dave BJ, Perry AM, et al. Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome. Leuk Lymphoma 2015;56:3085–3092.
- Lin CY, Loven J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012;151:56–67.
- Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005;436:807–811.
- Trabucco SE, Gerstein RM, Evens AM, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res 2015;21:113–122.